An anti-infective is any drug designed to kill or stop the growth of a disease-causing microorganism, whether that organism is a bacterium, virus, fungus, or parasite. The term is an umbrella that covers antibiotics, antivirals, antifungals, and antiparasitics, all united by a shared goal but differing enormously in how they achieve it. What makes any of them useful, rather than simply toxic, is their ability to exploit biological differences between the invading pathogen and your own cells.
Why Anti-Infectives Can Attack Pathogens Without Destroying You
The foundational idea behind every anti-infective goes back to a concept called selective toxicity. The goal is to find something that a pathogen needs to survive but that your body either lacks entirely or handles so differently that the drug barely touches your own biology. Beta-lactam antibiotics, for instance, work because they latch onto proteins involved in building the bacterial cell wall, a structure human cells simply do not have. Sulfonamides block a step in folic acid production that bacteria must carry out internally; human cells skip that step altogether and absorb folic acid from food instead.1SpringerOpen. Selective toxicity of antibacterial agents—still a valid concept or do we miss chances and ignore risks? This principle of exploiting unique microbial targets runs through every class of anti-infective, from antifungals that disrupt fungal membranes to antivirals that interfere with viral enzymes your cells never produce.
The principle is not perfect, though. Human cells share more molecular machinery with fungi than with bacteria, which is one reason antifungal drugs tend to have more side effects than typical antibiotics. And some antibacterials interact with structures inside human mitochondria, which descended from ancient bacteria and still share certain features with them. These off-target effects can show up as blood-cell abnormalities, bone marrow suppression, and other toxicities that blur the line between “anti-pathogen” and “anti-host.”2SpringerLink (Cancer Chemotherapy and Pharmacology). Off-target anti-leukemic effects of antibiotics: mechanisms and therapeutic insights
Antibacterials and Their Mechanisms
Antibacterials, commonly called antibiotics, form the largest and most familiar class of anti-infectives. They work by targeting structures or processes that bacteria rely on but human cells do not, and several distinct strategies exist.
Disrupting the Cell Wall
Bacteria are surrounded by a rigid cell wall made largely of a mesh-like molecule called peptidoglycan. Building that wall requires multiple steps, and different antibiotics interrupt different stages. Beta-lactams (penicillins, cephalosporins, carbapenems) block the final cross-linking step, causing the wall to weaken until the bacterium bursts. Glycopeptides like vancomycin bind to the building blocks themselves, preventing them from being incorporated. Fosfomycin and D-cycloserine hit even earlier stages of the assembly line.3The Microbe. Cell wall synthesis inhibitors with an emphasis on mode of actions, resistance mechanisms, and clinical utility and dosages Because human cells lack peptidoglycan entirely, cell-wall-targeting antibiotics tend to be well tolerated.
Blocking Protein Production
Bacteria build proteins on ribosomes that differ structurally from the ribosomes inside human cells, giving drugs a way to shut down bacterial protein synthesis without silencing yours. The ribosome has a few vulnerable spots, and different antibiotic classes exploit different ones. Aminoglycosides (gentamicin, tobramycin) bind the site where the ribosome reads genetic instructions, causing it to misread and produce garbled proteins. Oxazolidinones (linezolid) block the site where new amino acids are linked together. Macrolides (azithromycin, erythromycin) plug the tunnel that newly made protein chains travel through as they exit the ribosome.4PubMed. Antibiotics that target protein synthesis 5PubMed Central. From Erythromycin to Azithromycin and New Potential Ribosome-Binding Antimicrobials
Targeting DNA Machinery
Fluoroquinolones (ciprofloxacin, levofloxacin) work by interfering with the enzymes bacteria use to coil, uncoil, and repair their DNA. Without functional DNA-handling enzymes, bacteria cannot replicate or repair damage, and they die.6PubMed Central. Mode of action of sulfanilyl fluoroquinolones Because the human versions of these enzymes are structurally different, fluoroquinolones are reasonably selective, though they carry a wider side-effect profile than cell-wall drugs.
How Antivirals Work
Viruses present a fundamentally different challenge. They are not free-living cells; they hijack your own cellular machinery to reproduce. That makes it harder to find targets that belong to the virus alone. Still, every virus has steps in its life cycle that depend on viral-specific proteins, and antivirals are designed to jam those steps.
The list of possible targets reads like a timeline of a viral infection. Some drugs block attachment to or entry into host cells. Others prevent the virus from shedding its protein coat once inside. Polymerase inhibitors stop the virus from copying its genetic material. Protease inhibitors prevent the virus from chopping up large precursor proteins into the smaller functional pieces it needs to assemble new virus particles.7PubMed Central. A review: Mechanism of action of antiviral drugs Viral proteases are attractive targets because they play a critical role in the viral life cycle, and blocking them can prevent a virus from producing the structural components needed for new copies.8PubMed Central. Protease inhibitors as antiviral agents
HIV treatment illustrates how multiple antiviral strategies can be layered. Integrase inhibitors, for example, prevent HIV from stitching its genetic code into the DNA of your immune cells, a step the virus absolutely requires to reproduce. Raltegravir was the first drug in this class to reach the market, and it specifically blocks the “strand transfer” step where viral DNA gets inserted into a host chromosome.9Clinical Infectious Diseases. Raltegravir: The First HIV Type 1 Integrase Inhibitor Modern HIV regimens combine drugs that hit different viral targets simultaneously, making it much harder for the virus to develop resistance to all of them at once.
Antifungals and the Ergosterol Problem
Fungi are closer relatives to humans than bacteria are, which makes finding selective drug targets trickier. The main exploitable difference lies in fungal cell membranes. While human cell membranes use cholesterol as a key structural component, fungal membranes rely on a related molecule called ergosterol. Most antifungal drugs take aim at ergosterol in one way or another.
Azole antifungals (fluconazole, voriconazole, posaconazole) block an enzyme in the ergosterol-production pathway, starving the fungal membrane of the molecule it needs to stay intact.10PubMed Central. Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance Polyene antifungals like amphotericin B take a more direct approach: they physically bind to ergosterol molecules already sitting in the membrane, punching holes that cause the cell’s contents to leak out. Because human cholesterol is structurally similar, polyenes can also interact with human membranes to some degree, which is why amphotericin B is notorious for kidney toxicity.
A third class, the echinocandins (caspofungin, micafungin, anidulafungin), sidesteps the membrane issue entirely. These drugs block the enzyme that builds beta-1,3-glucan, a sugar polymer that forms the scaffolding of the fungal cell wall.11PubMed Central. Echinocandins – structure, mechanism of action and use in antifungal therapy 12PubMed Central. Inhibition mechanism of the fungal β-1,3-glucan synthases by triterpenoid antifungal drugs Human cells do not make beta-1,3-glucan, so echinocandins tend to be gentler on the body than amphotericin B. The trade-off is that they only work against fungi that depend heavily on this particular wall component, which limits their range.
Resistance in fungi can be creative. Some species reroute their sterol-production pathway to avoid making the toxic byproducts that azoles normally trigger, rendering the drugs ineffective. Others alter the composition of their membranes so that amphotericin B can no longer bind ergosterol properly.13PubMed Central. Alternative ergosterol biosynthetic pathways confer antifungal drug resistance in the human pathogens within the Mucor species complex
Antiparasitic Drugs
Parasites range from single-celled organisms like the one causing malaria to large worms visible to the naked eye, and the drugs used against them are correspondingly diverse. For intestinal worm infections, benzimidazoles such as albendazole and mebendazole are workhorses. They disrupt the structural scaffolding inside parasite cells, which starves the worm by blocking its ability to take up glucose.14PubMed Central. Albendazole and Mebendazole as Anti-Parasitic and Anti-Cancer Agents: an Update
For protozoal infections like giardiasis, nitroimidazole drugs (metronidazole, tinidazole) are the standard. A course of metronidazole lasting five to seven days cures over 90 percent of giardia infections, and a single dose of tinidazole achieves a similar rate.15PubMed Central. Treatment of giardiasis These drugs work by generating reactive molecules that damage the parasite’s DNA once they are activated inside its oxygen-poor environment.
Broad Spectrum Versus Narrow Spectrum
Anti-infectives vary dramatically in how many types of organisms they affect. A narrow-spectrum drug targets a small group, while a broad-spectrum one hits many species at once. Both approaches have trade-offs, and nowhere is the distinction more consequential than in your gut.
Your intestines harbor hundreds of bacterial species that contribute to digestion, immune regulation, and defense against harmful organisms. Broad-spectrum antibiotics do not distinguish between dangerous bacteria and beneficial residents. A large study of nearly 15,000 people found that six of eleven antibiotic classes used within the prior year were linked to measurably lower diversity of gut bacteria. The heaviest hitters were clindamycin, fluoroquinolones, and flucloxacillin. Each course of clindamycin was associated with roughly 47 fewer species detected in stool samples, and the effects of fluoroquinolones and clindamycin persisted for years after treatment ended. By contrast, some narrower-spectrum options like pivmecillinam and amoxicillin showed no detectable association with reduced diversity.16Nature Medicine. Antibiotic use and gut microbiome composition links from individual-level prescription data of 14,979 individuals
The clinical stakes are real. Disruption of gut bacteria creates an ecological vacuum that the dangerous bacterium Clostridioides difficile can exploit, causing severe diarrhea and colitis. Both fluoroquinolones and clindamycin are well known for elevating C. difficile risk. Experimental work in gut models shows that narrow-spectrum agents targeting C. difficile specifically can kill it just as effectively as broad-spectrum drugs without the collateral damage to surrounding microbial communities.17PubMed Central. Effect of broad- and narrow-spectrum antimicrobials on Clostridium difficile and microbial diversity in a model of the distal colon This is a growing area of research: finding ways to eliminate pathogens precisely, the way a sniper round removes a target, rather than carpet-bombing the entire ecosystem.
How Microbes Develop Resistance
Every class of anti-infective faces the same evolutionary pressure. Microorganisms reproduce fast, and any mutation that helps one survive a drug gets passed along rapidly. Several resistance strategies show up across different types of pathogens.
One common trick is the efflux pump, a molecular doorway in the microbe’s membrane that actively pushes the drug back out before it can do damage. Some efflux pumps are specific to a single drug, while others can expel a range of chemically unrelated compounds, making the microbe resistant to multiple drugs at once. Drug-specific pumps tend to be carried on mobile genetic elements that bacteria swap between each other, spreading resistance through a population like a shared playbook.18PubMed. Efflux pumps as antimicrobial resistance mechanisms
Another strategy involves biofilms. When bacteria form biofilms, they cluster together on a surface and encase themselves in a sticky matrix of sugars, proteins, and DNA. This matrix acts as a physical barrier that slows drug penetration, while the bacteria inside shift into a slow-growing, hibernation-like state that makes them far less vulnerable to drugs designed to attack rapidly dividing cells.19FEMS Microbiology Reviews. Molecular mechanisms of biofilm-based antibiotic resistance and tolerance in pathogenic bacteria Biofilm-related infections on medical implants, heart valves, and chronic wounds are among the hardest to treat for exactly this reason.
Combination Strategies to Outmaneuver Resistance
When a single drug is no longer enough, combining it with a second agent that disables the microbe’s defense mechanism can restore effectiveness. The most successful version of this strategy pairs an antibiotic with an inhibitor of the very resistance mechanism the bacterium uses against it.
Beta-lactamase inhibitors are the best-established example. Many resistant bacteria produce enzymes called beta-lactamases that break apart beta-lactam antibiotics before they can reach their target. Pairing the antibiotic with a molecule that blocks that enzyme, such as clavulanic acid (the “clav” in amoxicillin-clavulanate), lets the antibiotic work again. The same principle has been extended to outer membrane permeabilizers that help drugs get inside gram-negative bacteria, and to efflux pump inhibitors that prevent bacteria from expelling drugs.20PubMed. β-Lactamase Inhibitors To Restore the Efficacy of Antibiotics against Superbugs Newer beta-lactamase inhibitors like zidebactam, taniborbactam, and xeruborbactam are being tested against strains resistant to even the latest-generation antibiotics, and early results show they can significantly restore drug activity.21PubMed Central. Sporadic cefiderocol resistance in Escherichia coli from the United Arab Emirates involves multifactorial mechanisms reversible by novel beta-lactamase inhibitors
HIV treatment, as mentioned earlier, is another landmark example of combination therapy. Using three or more drugs that hit different viral targets has transformed HIV from a death sentence into a manageable chronic condition, precisely because the virus cannot easily mutate away from all targets simultaneously.
Getting the Drug to the Right Place
An anti-infective that works beautifully in a test tube can fail in the body if it never reaches the site of infection in adequate concentration. The body is not a uniform soup; different tissues have barriers that limit drug entry.
The brain is the most extreme example. The blood-brain barrier is a tightly sealed layer of cells that keeps most molecules out of the central nervous system. Whether an anti-infective crosses this barrier depends on its size, electrical charge, fat solubility, how much of it rides around bound to proteins in the blood, and whether it hitches a ride on active transport systems built into the barrier. Meningeal inflammation actually loosens the barrier somewhat, which is why certain antibiotics that normally cannot reach the brain become more effective during meningitis.22PubMed Central. Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections Similar access problems exist for infections in bone, the prostate, and abscesses, where poor blood supply or walled-off pockets of pus limit how much drug gets through.
This is why the same bacterium can require different antibiotics depending on where in the body the infection sits. A urinary tract infection might clear with an oral drug that concentrates in urine, while the same bug growing on a heart valve demands weeks of intravenous therapy with a drug chosen specifically for its ability to penetrate heart tissue.
Emerging Approaches Beyond Traditional Drugs
As resistance narrows the list of effective conventional anti-infectives, researchers are looking in unexpected directions. Two of the most actively studied alternatives are bacteriophages and antimicrobial peptides.
Bacteriophages, or phages, are viruses that infect and kill bacteria while leaving human cells alone. Each phage is typically specific to one bacterial species or even one strain, which gives it the narrow-spectrum precision that avoids the gut-microbiome disruption caused by broad-spectrum antibiotics. Phages kill bacteria by latching onto specific surface receptors, injecting their genetic material, hijacking the bacterium’s replication machinery, and then bursting the cell open to release new phage copies. Clinical evidence so far comes mostly from compassionate-use cases and small series rather than large randomized trials, but results in patients with infections caused by multidrug-resistant organisms have been encouraging, particularly when conventional treatments had already failed.23PubMed. Bacteriophage therapy for multidrug-resistant bacterial infections: recent advances, clinical evidence, and translational challenges 24PubMed Central. Phage and Endolysin Therapy Against Antibiotics Resistant Bacteria: From Bench to Bedside
Antimicrobial peptides take a different approach. These are small protein fragments, many of which your own immune system already produces, that can punch holes in bacterial membranes or trigger immune responses. Some peptides self-assemble into microscopic nets that physically trap bacteria, preventing invasion and spread. Because this mechanism of killing does not depend on a single molecular target, it is harder for bacteria to evolve resistance against it the way they do against conventional antibiotics.25PubMed. Combating bacterial infections with host defense peptides: Shifting focus from bacteria to host immunity Turning these peptides into practical drugs has been slow going, since many are fragile and break down quickly in the body, but engineered versions with improved stability are moving toward clinical testing.
Where New Anti-Infectives Come From
Most anti-infectives in clinical use trace their origins to natural sources. Soil-dwelling bacteria and fungi produce antibiotics as chemical weapons against their microbial competitors, and the majority of antibiotic classes in medicine were originally discovered by screening these organisms. Modern discovery efforts blend older microbiology-based approaches with chemistry and molecular biology techniques, mining underexplored environments like deep-sea sediments and cave ecosystems for organisms that might produce novel compounds.26PubMed Central. Modern Trends in Natural Antibiotic Discovery
Synthetic chemistry has also become essential, particularly for antivirals and for tweaking natural antibiotic scaffolds to overcome resistance. The integration of genomic sequencing now allows researchers to identify gene clusters in bacteria that encode potentially useful compounds, even when those compounds are not produced under normal laboratory conditions. Activating these “silent” gene clusters, essentially tricking the organism into making something it would not ordinarily produce, is one of the more promising frontiers in the search for new anti-infectives. The pipeline remains thin relative to the scale of the resistance problem, but the toolkit for finding candidates has expanded considerably.